期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

基质金属蛋白酶在子宫内膜癌中的表达及意义

Expression and Significance of Matrix Metalloproteinases in Endometrial Cancer
下载PDF
导出
摘要 基质金属蛋白酶(MMPs)是一族锌离子依赖的蛋白水解酶,MMPs及其组织抑制因子(TIMPs)共同参与多种生理、病理过程。不同的MMPs及TIMPs分别与子宫内膜癌患者的发病年龄、临床分期、浸润深度、腹膜细胞是否受累、组织学分级等具有相关性,MMPs-TIMPs平衡的打破也有利于肿瘤的扩散。近年的研究显示,MMPs有望作为子宫内膜癌的诊断工具及判断预后的标志物,人工合成的基质金属蛋白酶抑制剂可能成为治疗子宫内膜癌的新手段。 The matrix metalloproteinases（MMPs） are a family of zinc-dependent proteolytic enzymes,MMPs and their tissue inhibitors factor（TIMPs） participate in a variety of physiological and pathological processes.Different MMPs and TIMPs are correlated to the age of onset in patients with endometrial cancer,clinical stage,depth of invasion,whether peritoneal cells are involved,and histological grade.The disruption of the MMPs-TIMPs balance may be a favorable event for tumor dissemination.In recent years,studies have shown that MMPs are expected to be used as a diagnostic tool for endometrial cancer and prognostic markers,and synthetic matrix metalloproteinase inhibitor may become a new treatment of endometrial cancer.
作者 李鸿儒 关源源
机构地区 哈尔滨医科大学附属第一临床医院生殖科
出处 《医学综述》 2013年第5期807-810,共4页 Medical Recapitulate
关键词 子宫内膜肿瘤 基质金属蛋白酶 金属蛋白酶类组织抑制剂 Endometrial tumor Matrix metalloproteinase Tissue inhibitor of metalloproteinases
分类号 R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献33

  • 1Chang C,Werb Z.The many faces of metalloproteases:cell growth,invasion,angiogenesis and metastasis[J].Trends Cell Biol,2001,11(11):S37-S43.
  • 2Rodgers WH,Osteen KG,Matrisian LM,et al.Expression and lo-calization of matrilysin,a matrix metalloproteinase,in human endo-metrium during the reproductive cycle[J].Am J Obstet Gynecol,1993,168(1Pt1):253-260.
  • 3Hampton AL,Salamonsen LA.Expression of messenger ribonucleicacid encoding matrix metalloproteinases and their tissue inhibitors isrelated to menstruation[J].J Endocrinol,1994,141(1):R1-R3.
  • 4Goffin F,Munaut C,Frankenne F,et al.Expression pattern of metallo-proteinases and tissue inhibitors of matrix-metalloproteinases in cyclinghuman endometrium[J].Biol Reprod,2003,69(3):976-984.
  • 5Graesslin O,Cortez A,Fauvet R,et al.Metalloproteinase-2,-7 and-9 and tissue inhibitor of metalloproteinase-1 and-2 expression innormal,hyperplastic and neoplastic endometrium:a clinical-patho-logical correlation study[J].Ann Oncol,2006,17(4):637-645.
  • 6Curry TE Jr,Osteen KG.The matrix metalloproteinase system:changes,regulation,and impact throughout the ovarian and uterinereproductive cycle[J].Endocr Rev,2003,24(4):428-465.
  • 7Becher N,Hein M,Uldbjerg N,et al.Balance between matrix metal-loproteinases(MMP)and tissue inhibitors of metalloproteinases(TIMP)in the cervical mucus plug estimated by determination offree non-complexed TIMP[J].Reprod Biol Endocrinol,2008,6:45.
  • 8Torng PL,Mao TL,Chan WY,et al.Prognostic significance of stromalmetalloproteinase-2 in ovarian adenocarcinoma and its relation to car-cinoma progression[J].Gynecol Oncol,2004,92(2):559-567.
  • 9Brinckerhoff CE,Rutter JL,Benbow U.Interstitial collagenases asmarkers of tumor progression[J].Clin Cancer Res,2000,6(12):4823-4830.
  • 10Ueda M,Terai Y,Kumagai K,et al.Vascular endothelial growth fac-tor C gene expression is closely related to invasion phenotype in gy-necological tumor cells[J].Gynecol Oncol,2001,82(1):162-166.

二级参考文献38

  • 1HU J, van DEN STEEN PE, SANG QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases[J]. Nat Rev Drug Discov, 2007, 6(6): 480- 498.
  • 2SANG QX, JIN Y, NEWCOMER RG, et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases[J]. Curr Top Med Chem, 2006, 6(4): 289-316.
  • 3FOLGUERAS AR, PENDAS AM, SANCHEZ LM, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies[J]. Int J Dev Biol, 2004, 48 (5-6): 411- 424.
  • 4PEI D, KANG T, QI H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type Ⅱ transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation[J]. J Biol Chem, 2000, 275(43): 33988-33997.
  • 5SKILES JW, GONNELLA NC, JENG AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors [J]. Curr Med Chem, 2001, 8(4) : 425-474.
  • 6LOVEJOY B, HASSELL AM, LUTHER MA, et al. Crystal structures of recombinant 19-kDa human flbroblast collagenase complexed to itself[J]. Biochemistry, 1994, 33 (27): 8207- 8217.
  • 7CROSS JB, DUCA JS, KAMINSKI J J, et al. The active site of a zinc-dependent metalloproteinase influences the computed pK (a)of ligands coordinated to the catalytic zinc ion[J]. J Am Chem Soc, 2002,124(37): 11004-11007.
  • 8AUGE F, HOMEBECK W, DECAME M, et al. Improved gelatinase a selectivity by novel zinc binding groups containing galardin derlvatives[J]. Bioorg Med Chem Lett, 2003, 13 (10):1783-1786.
  • 9GALL AL, RUFF M, KANNAN R, et al. Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state [J]. J Mol Biol, 2001, 307(2): 577-586.
  • 10MICHAELIDES MR, DELLARIA JF, GONG J, et al. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors[J]. Bioorg Med Chem Lett, 2001, 11 (12) : 1553 - 1556.

共引文献14

医学综述
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部